The changing face of the generics industry
The pace of corporate consolidation grows ever faster. Nine acquisitions were announced in 2006 including well known companies such as Andrx and Pliva. Increasingly the industry is being rationalised and dominated by fewer and fewer larger players. Teva and Sandoz may be fighting it out for the top spot but the speed of change is seeing the corporate landscape change continuously.

Emerging markets to 2011
Established generic markets may currently account for the bulk of generic prescribing and value, but where is the industry going in the future? In terms of growth not one of the leading markets features, but look to France, Spain, Brazil and Italy if you want significant double digit growth to 2011. To understand the generic market, Espicom, the publisher of the respected twice-monthly business publication World Generic Markets, has published The World Generic Market Report 2007. Packed with facts, figures, analysis and statistics, the 480+ page report provides the most thorough report available on generic markets, products and companies and the issues they face.

Industry consolidation, emerging generic markets, biosimilars plus much, much more
Published in November 2006, this report draws on primary research with companies, statistics offices, health ministries and trade associations worldwide and provides standard, comparative data and discussion on key issues such as:

Industry consolidation and the emergence of “super” generic companies
Double digit generic market growth - but where?
Biosimilars: now live in Europe - but elsewhere?
Authorised generics and other 180-day exclusivity issues in the US
Key legal challenges
The political and funding background
Intellectual property issues

Report Contents

Global Overview

Industry consolidation
Current issues in the USA
The widening influence of India
WTO Agreement

Biosimilars
Current issues in the European Union
Prospects for growth.

Country Market Data Covering:
Key facts
Generic market value & 5-year forecast
Patent protection/IP
Pricing/reimbursement.

Countries covered:
Australia
Brazil
Canada
France
Germany
India
Italy
Japan
Netherlands
South Africa
Spain
UK
Switzerland
USA

Company Data Covering:
Financial Performance
ANDAs and launched products

M&A activity and litigation.

Companies covered:
Apotex
Aspen Pharmacare
Barr Laboratories
Cipla
Dr Reddy's
EGIS
Hospira
KRKA
Lannett
Mayne Pharma
Merck Generics
Mylan Labs
Par Pharmaceuticals
Perrigo
Pliva
Ranbaxy
ratiopharm
Gedeon Richter
Sandoz
Sawai
Stada Arzneimittel
Teva Pharmaceutical Industries
Towa Pharmaceuticals
Watson Pharmaceuticals
Winthrop
Wockhardt
Zentiva
Zydus Cadila